No definition available.
Drug-induced headache, not elsewhere classified
DRUGADVERS_HEADA_NOT_ELSEW_CLASSIFIED
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
520210 |
1. Apply sex-specific ruleNone |
520210 |
2. Check conditionsNone |
520210 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
1 out of 7 registries used, show all original rules. |
196 |
4. Check minimum number of eventsNone |
196 |
5. Include endpointsNone |
196 |
6. Filter based on genotype QC (FinnGen only) |
196 |
Control definitions (FinnGen only)
Controls for this endpoint are individuals that are not cases.
Extra metadata
- Level in the ICD hierarchy
- C
- First used in FinnGen datafreeze
- DF5
Similar endpoints
↥List of similar endpoints to
Drug-induced headache, not elsewhere classified
based on the number of shared cases.
Similar with more cases:
- Other headache syndromes
- Episodal and paroxysmal disorders
- Neurological diseases
- Neurological diseases, wide definition
- Any event in hilmo or specialist outpatient
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 1129 | 777 | 342 |
| Only index persons | 1067 | 749 | 318 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.02 | 0.02 | 0.01 |
| Only index persons | 0.02 | 0.03 | 0.01 |
| Median age at first event (years) | |||
| Whole population | 46.97 | 46.58 | 48.11 |
| Only index persons | 46.83 | 46.39 | 47.85 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 196 | 155 | 41 |
| Unadjusted period prevalence (%) | 0.05 | 0.05 | 0.02 |
| Median age at first event (years) | 48.48 | 46.97 | 54.16 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 183
- Matched controls
- 1827
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
G44.4
ICD-10 Finland
Drug-induced headache, not elsewhere classified
+∞
264.8
183
*
G43.0
ICD-10 Finland
Migraine without aura [common migraine]
21.0
56.8
91
82
N03AX11
ATC
topiramate; oral
29.1
43.9
60
30
G43.3
ICD-10 Finland
Complicated migraine
42.1
42.1
52
17
R51.80
ICD-10 Finland
Headache
10.7
42.1
98
178
G44.2
ICD-10 Finland
Tension-type headache
10.0
37.8
89
158
N02CC01
ATC
sumatriptan; nasal, systemic, rectal
8.5
35.7
97
214
G43.9
ICD-10 Finland
Migraine, unspecified
12.4
34.8
68
83
N02CC07
ATC
frovatriptan; oral
14.6
30.7
54
51
3007
Kela drug reimbursment
Erenumab and fremanezumab
41.7
30.1
37
11
N02CD01
ATC
erenumab; parenteral
55.0
27.5
32
7
C09CA06
ATC
candesartan; oral
6.4
27.4
91
245
N06CA01
ATC
amitriptyline and psycholeptics; systemic
8.2
26.5
66
117
N02CC04
ATC
rizatriptan; oral
10.2
26.0
55
74
N03AG01
ATC
valproic acid; systemic, rectal
11.8
25.4
49
55
G43.1
ICD-10 Finland
Migraine with aura [classical migraine]
9.5
24.6
54
77
G43
ICD-10 Finland
Migraine
12.2
24.4
46
49
N02CC05
ATC
almotriptan; oral
13.0
23.7
43
42
N02CC06
ATC
eletriptan; oral
11.7
21.5
41
44
N02CC03
ATC
zolmitriptan; nasal, oral
9.1
21.2
47
67
N02CD03
ATC
fremanezumab; systemic
47.9
21.1
25
6
N02CC02
ATC
naratriptan; oral
24.3
20.7
29
14
N06AA09
ATC
amitriptyline; systemic
7.4
20.5
53
96
N03AX12
ATC
gabapentin; oral
6.1
19.3
59
133
M03AX01
ATC
botulinum toxin; parenteral
34.2
18.9
24
8
N03AX16
ATC
pregabalin; oral
4.6
17.8
74
233
N01
ICPC
Headache
6.0
17.4
53
117
G43.8
ICD-10 Finland
Other migraine
18.7
17.1
26
16
A03FA01
ATC
metoclopramide; systemic, rectal
4.4
16.6
73
239
N06AX21
ATC
duloxetine; oral
5.8
16.3
50
111
C07AA05
ATC
propranolol; systemic
4.2
16.0
76
266
N89
ICPC
Migraine
9.7
15.6
32
39
C07AB02
ATC
metoprolol; systemic
4.7
14.8
56
156
N02AX02
ATC
tramadol; systemic, rectal
3.5
14.5
103
491
M01AG02
ATC
tolfenamic acid; oral, rectal
4.0
14.4
68
233
A02BC03
ATC
lansoprazole; oral
3.7
14.2
82
331
G44.0
ICD-10 Finland
Cluster headache syndrome
16.8
13.5
21
14
N05BA01
ATC
diazepam; systemic, rectal
4.9
12.8
45
114
C07AB07
ATC
bisoprolol; oral
3.2
12.8
98
482
N06AX16
ATC
venlafaxine; oral
4.4
12.6
51
149
M03BX02
ATC
tizanidine; oral
3.5
12.3
144
944
A02BC02
ATC
pantoprazole; systemic
3.3
12.2
138
877
C08DA01
ATC
verapamil; systemic
9.6
11.4
23
27
M79.1
ICD-10 Finland
Myalgia
4.2
11.3
46
135
A02BA02
ATC
ranitidine; systemic
3.6
10.8
54
189
N02CA52
ATC
ergotamine, combinations excl. psycholeptics; oral
25.1
10.4
14
6
A02BC05
ATC
esomeprazole; systemic
2.8
10.3
98
528
R10.4
ICD-10 Finland
Other and unspecified abdominal pain
2.8
10.1
94
499
AA1AD
NOMESCO Finland
CT of head and brain
3.3
9.8
56
214
R53
ICD-10 Finland
Malaise and fatigue
3.3
9.8
57
222
Z01.8
ICD-10 Finland
Other specified special examinations
3.2
9.6
61
250
M01AE02
ATC
naproxen; oral, rectal
2.8
9.5
130
854
N06AA10
ATC
nortriptyline; systemic
11.6
9.5
17
16
M03BC51
ATC
orphenadrine, combinations; systemic
2.8
9.4
75
360
N02CX04
ATC
NA
12.4
9.3
16
14
N06AX11
ATC
mirtazapine; oral
2.7
8.9
80
409
M03BC01
ATC
orphenadrine (citrate); systemic
2.9
8.9
64
286
H02AB06
ATC
prednisolone; systemic
2.6
8.9
105
624
F32.9
ICD-10 Finland
Depressive episode, unspecified
3.7
8.8
41
134
R51
ICD-10 Finland
Headache
5.2
8.8
27
59
G43.2
ICD-10 Finland
Status migrainosus
29.1
8.6
11
*
N05AH04
ATC
quetiapine; oral
3.2
8.5
49
186
H02AB07
ATC
prednisone; oral
3.3
8.4
46
170
N02BE01
ATC
paracetamol; systemic, rectal
3.8
8.2
167
1339
M01AE03
ATC
ketoprofen; systemic, rectal
2.5
7.9
83
454
F32.10
ICD-10 Finland
Moderate depressive episode without somatic syndrome
3.8
7.9
34
104
AA1CG
NOMESCO Finland
Extensive MRI examination of brain with high intensity magnet
4.3
7.8
29
77
R10.3
ICD-10 Finland
Pain localized to other parts of lower abdomen
2.7
7.8
64
303
N02CD02
ATC
galcanezumab; parenteral
47.0
7.8
9
*
N06AB04
ATC
citalopram; systemic
2.8
7.6
57
256
N02AA59
ATC
codeine, combinations excl. psycholeptics; systemic
2.4
7.6
101
619
N03AX09
ATC
lamotrigine; oral
5.4
7.6
22
45
A06AC01
ATC
ispaghula (psylla seeds); oral
2.7
7.4
60
281
AA1BG
NOMESCO Finland
Standard MRI examination of brain with high intensity magnet
4.4
7.4
26
66
R07.4
ICD-10 Finland
Chest pain, unspecified
2.8
7.3
55
246
Z76.0
ICD-10 Finland
Issue of repeat prescription
3.1
7.2
43
167
N03AE01
ATC
clonazepam; systemic
4.7
7.0
23
54
N05BA04
ATC
oxazepam; oral
2.5
6.9
62
307
M01AB05
ATC
diclofenac; systemic, rectal
2.4
6.9
135
985
K07.61
ICD-10 Finland
Cracking jaw joint
12.9
6.7
11
9
SHB00
NOMESCO Finland
Prepation and fitting of bite rail to mouth
3.1
6.6
37
137
R10.1
ICD-10 Finland
Pain localized to upper abdomen
2.8
6.6
44
183
N06AX12
ATC
bupropion; oral
4.3
6.5
23
59
N02CA01
ATC
dihydroergotamine; nasal, systemic
18.8
6.3
9
5
R42
ICD-10 Finland
Dizziness and giddiness
2.6
6.3
48
217
P01AB01
ATC
metronidazole; oral, rectal
2.2
6.3
87
528
G44.3
ICD-10 Finland
Chronic post-traumatic headache
+∞
6.3
6
*
SPAT1050
SPAT
Extensive neurological examination
9.1
6.2
12
14
N06AB03
ATC
fluoxetine; oral
3.0
6.1
37
143
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
118
686
2.81
11.22
8.5
5.7
1.2
1.2
mmol/l
0.33
106
571
74
358
2.71
9.83
2.6
1.9
2.9
2.9
mg/l
0.02
62
308
166
1213
3.41
9.42
4.4
3.9
9.9
10.2
mm/h
0.11
160
1123
105
615
2.52
9.25
4.2
4.3
37.2
36.3
g/l
0.94
98
576
124
791
2.55
9.00
4.3
2.8
71.5
83.3
ug/l
0.78
118
736
98
565
2.47
8.82
2.2
1.8
95.0
100.3
pmol/l
0.55
49
291
138
943
2.57
8.38
10.9
9.0
3.8
4.0
e9/l
1.02
125
833
71
369
2.45
7.84
1.9
1.7
0.9
0.8
mg/l
0.24
49
285
103
634
2.32
7.69
6.4
4.9
1.2
1.2
mmol/l
0.44
97
571
79
437
2.35
7.54
3.5
2.0
106.3
327.2
u/l
0.85
74
418
168
1294
3.09
7.54
5.8
4.1
14.3
14.5
pmol/l
0.68
160
1202
48
223
2.53
6.62
3.8
2.4
5.8
3.1
e6/l
0.66
25
118
89
552
2.12
6.14
3.1
3.4
14.6
39.9
ng/l
1.62
38
325
16
40
4.27
6.02
1.3
1.1
3.3
3.0
e6/l
—
10
32
52
261
2.35
6.02
2.6
2.7
2.4
2.4
mmol/l
0.71
45
227
72
414
2.17
6.01
1.5
1.2
0.5
1.5
u/ml
1.75
15
125
22
71
3.36
5.82
1.4
2.6
35.6
41.6
u/l
0.80
22
65
85
528
2.08
5.75
4.1
2.8
—
—
—
0
0
182
1534
3.61
5.67
6.9
4.8
1.7
2.6
mu/l
0.58
174
1423
48
242
2.30
5.46
3.4
2.3
1.6
1.0
e6/l
0.64
26
137
61
343
2.13
5.30
2.4
2.9
864.0
733.2
ng/l
0.13
48
287
154
1227
2.19
4.89
9.1
6.8
74.3
76.7
u/l
0.43
146
1143
46
240
2.20
4.78
1.6
1.6
1153.7
1205.4
nmol/l
0.13
36
179
18
58
3.32
4.77
1.4
1.6
—
—
—
0
0
68
420
1.95
4.46
3.5
2.6
0.0
0.4
e6/l
3.40
46
310
48
263
2.09
4.38
5.6
3.2
58.3
109.4
ng/l
0.46
27
169
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
8
9
9.20
4.32
1.4
1.2
—
—
—
0
0
7
6
12.03
4.31
1.4
1.2
—
—
—
0
0
176
1526
2.50
3.87
15.9
10.5
86.3
86.7
ml/min/173m2
0.08
158
1227
55
330
1.93
3.86
1.3
1.3
13.2
32.1
iu/ml
2.22
15
110
17
62
2.91
3.69
1.9
1.5
—
—
—
0
0
15
52
3.04
3.55
1.9
1.7
—
—
—
0
0
186
1672
3.20
3.50
20.9
11.7
17.5
19.6
mg/l
0.55
155
1258
75
510
1.76
3.48
2.3
3.0
2.3
2.3
mmol/l
1.11
64
457
114
878
1.71
3.34
6.6
3.8
6.2
6.5
mmol/l
0.83
109
802
22
97
2.43
3.34
1.6
1.5
—
—
—
0
0
38
211
1.99
3.31
2.1
1.7
—
—
—
0
0
6
7
8.79
3.28
1.2
1.1
—
—
%
—
0
0
24
113
2.28
3.16
1.3
1.3
108.3
329.6
u/ml
0.50
24
99
147
1225
1.80
3.16
4.0
3.4
—
—
—
0
0
47
285
1.85
3.15
1.5
1.7
454.3
434.9
pmol/l
0.24
40
249
5
5
10.21
2.99
1.0
1.2
—
—
—
0
0
14
53
2.77
2.86
1.6
1.7
—
—
—
0
0
49
315
1.74
2.69
1.3
1.3
1.2
7.7
u/ml
2.28
23
140
7
15
4.80
2.62
1.1
1.1
—
—
—
0
0
188
1751
2.80
2.60
13.5
9.2
25.5
24.8
u/l
0.17
188
1697
5
7
7.29
2.56
2.0
1.9
103.8
115.1
%
—
5
7
7
16
4.49
2.50
1.3
1.1
—
—
—
0
0
7
16
4.49
2.50
1.1
1.1
—
—
—
0
0
7
16
4.49
2.50
1.6
1.5
—
—
—
0
0
173
1552
1.98
2.48
4.4
4.0
5.6
5.8
mmol/l
2.53
163
1443
14
58
2.52
2.43
7.1
3.0
53.9
49.7
%
0.26
14
58
14
58
2.52
2.43
1.2
1.2
—
—
—
0
0
101
795
1.56
2.42
5.1
3.4
0.0
0.0
estimate
0.00
20
152
100
787
1.55
2.39
5.0
3.4
0.0
0.0
estimate
0.00
19
157
100
787
1.55
2.39
7.3
4.6
0.0
0.0
estimate
0.00
21
158
171
1533
1.91
2.39
3.8
3.5
1.3
1.3
mmol/l
0.70
161
1419
7
17
4.23
2.38
1.3
1.1
—
—
—
0
0
14
59
2.48
2.35
1.4
2.0
—
—
—
0
0
10
35
2.96
2.34
1.3
1.4
—
—
—
0
0
26
143
1.94
2.33
1.2
1.2
36.7
147.0
iu/ml
—
8
57
179
1636
2.09
2.25
4.9
4.3
2.9
2.8
mmol/l
0.25
171
1521
136
1166
1.54
2.06
3.5
2.8
35.7
40.6
u/l
0.59
131
1104
175
1601
1.87
1.99
4.3
3.9
1.5
1.5
mmol/l
0.73
165
1490
7
21
3.42
1.98
1.1
1.2
—
—
—
0
0
13
58
2.33
1.95
1.2
1.2
—
—
—
0
0
10
39
2.65
1.95
1.1
1.3
—
—
—
0
0
5
11
4.63
1.95
1.2
1.2
—
—
—
0
0
7
22
3.26
1.90
1.3
1.2
—
—
—
0
0
8
28
2.93
1.88
1.5
1.5
—
—
—
0
0
161
1451
1.61
1.79
4.8
4.9
37.1
38.9
mmol/mol
2.23
153
1369
19
104
1.92
1.74
2.1
2.2
0.2
0.2
g/l
0.74
14
99
11
48
2.37
1.74
5.4
3.5
24.6
25.0
mmol/l
0.33
11
48
5
13
3.92
1.72
8.0
8.4
0.5
0.7
mmol/l
—
5
13
29
183
1.69
1.69
2.4
2.3
4.0
6.6
umol/l
1.65
21
159
5
14
3.64
1.62
1.2
1.3
—
72.2
—
0
5
8
32
2.56
1.61
1.1
1.1
—
—
—
0
0
174
1611
1.71
1.59
4.5
3.9
4.8
4.8
mmol/l
0.15
166
1508
51
375
1.49
1.57
2.1
2.5
6431.2
5744.0
umol/l
0.04
44
333
5
15
3.39
1.53
1.0
1.1
—
—
—
0
0
52
386
1.47
1.53
1.7
1.5
—
—
—
0
0
35
239
1.57
1.51
2.4
1.9
—
—
—
0
0
12
59
2.10
1.47
3.4
2.6
1.7
1.2
%
0.48
12
59
11
53
2.14
1.41
1.1
1.2
—
—
—
0
0
16
90
1.85
1.37
3.2
1.9
53.0
4196.4
u/l
—
6
26
55
423
1.42
1.33
5.1
3.7
0.0
0.0
estimate
0.00
20
155
77
629
1.37
1.31
5.1
3.4
—
—
—
0
0
5
18
2.82
1.29
1.6
1.6
—
—
—
0
0
5
18
2.82
1.29
1.6
1.6
—
—
—
0
0
5
18
2.82
1.29
1.6
1.6
—
—
—
0
0
5
18
2.82
1.29
1.6
1.6
—
—
—
0
0
14
78
1.86
1.24
2.1
1.3
—
—
—
0
0
10
49
2.10
1.24
1.3
1.4
—
—
—
0
0
5
19
2.67
1.22
1.6
1.1
—
—
—
0
0
5
19
2.67
1.22
1.6
1.6
—
—
—
0
0
5
19
2.67
1.22
1.6
1.6
—
—
—
0
0
166
1545
1.49
1.18
23.6
12.1
38.4
40.4
%
1.76
134
1217
191
1848
2.31
1.17
29.8
17.6
133.6
134.5
g/l
0.46
191
1821
22
145
1.58
1.12
2.7
1.7
—
—
—
0
0
7
35
2.04
1.01
1.0
1.1
—
—
—
0
0
36
270
1.41
1.00
2.5
2.0
—
—
—
0
0
9
49
1.88
1.00
2.9
2.8
—
—
—
0
0
6
27
2.26
0.94
1.5
2.0
—
—
—
0
0
16
102
1.62
0.94
1.2
1.0
—
—
—
0
0
26
191
1.42
0.82
4.5
3.9
21.8
21.3
%
0.08
14
77
16
106
1.55
0.82
15.9
6.0
123.6
122.3
g/l
0.11
16
101
43
344
1.32
0.81
4.9
2.1
—
—
—
0
0
24
174
1.43
0.81
7.6
6.0
—
—
—
0
0
0
24
0.00
0.79
0.0
3.6
—
59.2
—
0
24
19
133
1.47
0.77
13.6
5.2
11.3
12.6
kpa
1.00
19
126
19
133
1.47
0.77
13.8
5.2
5.1
5.1
kpa
0.08
19
126
7
38
1.87
0.74
1.4
1.3
—
—
—
0
0
10
60
1.70
0.73
1.6
1.6
—
—
—
0
0
5
25
2.03
0.73
1.0
1.1
—
—
—
0
0
7
40
1.78
0.72
1.4
1.3
—
—
—
0
0
5
26
1.95
0.71
2.6
1.4
—
—
—
0
0
5
26
1.95
0.71
2.6
1.4
—
—
—
0
0
16
110
1.49
0.71
1.3
1.4
—
—
—
0
0
22
162
1.40
0.70
1.5
1.7
—
—
—
0
0
20
145
1.42
0.69
2.8
1.6
—
—
—
0
0
31
388
0.76
0.67
1.5
1.4
—
—
—
0
0
8
49
1.66
0.63
1.1
1.2
—
—
—
0
0
11
75
1.49
0.52
1.0
1.5
—
—
—
0
0
22
176
1.28
0.44
3.6
4.2
35.2
32.6
%
0.39
16
118
16
122
1.34
0.44
3.4
2.9
74.6
73.7
ml/min/173m2
—
10
50
10
139
0.70
0.43
2.0
3.3
—
—
—
0
0
8
57
1.42
0.42
1.1
1.7
—
—
—
0
0
5
33
1.53
0.41
2.8
2.0
25.6
24.5
mmol/l
—
5
26
16
125
1.30
0.38
1.5
1.6
—
—
—
0
0
9
73
1.24
0.26
3.8
1.7
—
—
—
0
0
10
78
1.30
0.24
1.4
1.5
539.3
270.6
mu/l
—
10
72
0
11
0.00
0.21
0.0
1.5
—
12.8
—
0
11
0
10
0.00
0.21
0.0
2.3
—
—
—
0
0
0
12
0.00
0.21
0.0
1.3
—
—
—
0
0
0
12
0.00
0.21
0.0
2.2
—
—
—
0
0
0
14
0.00
0.20
0.0
1.2
—
—
—
0
0
78
743
1.08
0.18
5.9
4.0
—
—
—
0
0
8
68
1.18
0.17
1.1
1.6
—
—
—
0
0
8
68
1.18
0.17
1.1
1.6
—
—
—
0
0
8
68
1.18
0.17
1.3
1.6
—
—
—
0
0
8
95
0.84
0.14
1.6
1.5
—
—
—
0
0
5
45
1.11
0.10
1.8
1.4
—
—
—
0
0
8
74
1.08
0.07
1.4
1.7
—
—
—
0
0
8
77
1.04
0.07
23.4
3.4
24.5
24.6
mmol/l
—
8
77
20
191
1.05
0.03
1.6
1.7
—
—
—
0
0
0
8
0.00
0.00
0.0
2.1
—
—
—
0
0
0
8
0.00
0.00
0.0
4.1
—
—
—
0
0
0
7
0.00
0.00
0.0
1.4
—
—
—
0
0
0
8
0.00
0.00
0.0
4.1
—
—
—
0
0
0
8
0.00
0.00
0.0
1.6
—
—
—
0
0
0
8
0.00
0.00
0.0
1.4
—
—
—
0
0
5
50
1.00
0.00
1.4
1.5
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
15.5
—
0
6
0
5
0.00
0.00
0.0
1.6
—
204.6
—
0
5
0
5
0.00
0.00
0.0
1.4
—
—
—
0
0
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
6
60
1.00
0.00
1.7
1.9
—
—
—
0
0
13
130
1.00
0.00
1.6
1.6
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint DRUGADVERS_HEADA_NOT_ELSEW_CLASSIFIED and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| DRUGADVERS_HEADA_NOT_ELSEW_CLASSIFIED | 1.32 [1.0, 1.74] | 0.046 |
| Birth year | 0.995 [0.99, 1.0] | 0.258 |
During the follow-up period (1.1.1998 — 31.12.2019), 76 out of 665 females with DRUGADVERS_HEADA_NOT_ELSEW_CLASSIFIED died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| DRUGADVERS_HEADA_NOT_ELSEW_CLASSIFIED | 1.614 [1.08, 2.4] | 0.019 |
| Birth year | 0.989 [0.98, 1.0] | 0.076 |
During the follow-up period (1.1.1998 — 31.12.2019), 56 out of 305 males with DRUGADVERS_HEADA_NOT_ELSEW_CLASSIFIED died.
Mortality risk
Mortality risk for people of age
years, who have DRUGADVERS_HEADA_NOT_ELSEW_CLASSIFIED.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.147% | 0.348% |
| 5 | 0.718% | 1.909% |
| 10 | 1.867% | 4.967% |
| 15 | 3.603% | 9.259% |
| 20 | 6.513% | 15.684% |
Relationships between endpoints
↥Index endpoint: DRUGADVERS_HEADA_NOT_ELSEW_CLASSIFIED – Drug-induced headache, not elsewhere classified
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data